{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:42:19Z","timestamp":1793731339915,"version":"4.6.1"},"reference-count":138,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81270795"],"award-info":[{"award-number":["81270795"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2012CB517700"],"award-info":[{"award-number":["2012CB517700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81321064"],"award-info":[{"award-number":["81321064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1053\/j.ajkd.2015.10.011","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T01:48:33Z","timestamp":1447811313000},"page":"728-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":436,"title":["Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials"],"prefix":"10.1053","volume":"67","author":[{"given":"Xinfang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9722","key":"10.1053\/j.ajkd.2015.10.011_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(09)62004-3","article-title":"Early recognition and prevention of chronic kidney disease","volume":"375","author":"James","year":"2010","journal-title":"Lancet"},{"issue":"9844","key":"10.1053\/j.ajkd.2015.10.011_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study","volume":"380","author":"Tonelli","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2015.10.011_bib4","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1681\/ASN.2007020256","article-title":"Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study","volume":"18","author":"Perkovic","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2015.10.011_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"issue":"9176","key":"10.1053\/j.ajkd.2015.10.011_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2015.10.011_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1053\/j.ajkd.2015.10.011_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2015.10.011_bib10","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7326\/0003-4819-144-3-200602070-00005","article-title":"Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate","volume":"144","author":"Rahman","year":"2006","journal-title":"Ann Intern Med"},{"issue":"28","key":"10.1053\/j.ajkd.2015.10.011_bib13","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib14","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2015.10.011_bib15","unstructured":"Dias S, Welton N, Sutton AJ, Ades AE. Appendix A: WinBUGS code used in Bayesian mixed treatment comparisons meta-analysis. In: NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. 2011; last updated March 2013. http:\/\/www.nicedsu.org.uk\/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf. Accessed January 2, 2015."},{"key":"10.1053\/j.ajkd.2015.10.011_bib16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"Alternative methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks SP","year":"1998","journal-title":"J\u00a0Comput Graph Stat"},{"issue":"7-8","key":"10.1053\/j.ajkd.2015.10.011_bib17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1053\/j.ajkd.2015.10.011_bib18","doi-asserted-by":"crossref","first-page":"d4909","DOI":"10.1136\/bmj.d4909","article-title":"Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study","volume":"343","author":"Song","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"23","key":"10.1053\/j.ajkd.2015.10.011_bib20","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1093\/eurheartj\/ehq139","article-title":"Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease","volume":"31","author":"Heerspink","year":"2010","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1053\/j.ajkd.2015.10.011_bib21","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2007.08.029","article-title":"The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial","volume":"50","author":"Brugts","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2015.10.011_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/CIRCULATIONAHA.105.592733","article-title":"Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial","volume":"114","author":"Solomon","year":"2006","journal-title":"Circulation"},{"issue":"7","key":"10.1053\/j.ajkd.2015.10.011_bib23","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1463-1326.2005.00514.x","article-title":"The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency","volume":"8","author":"Tong","year":"2006","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1053\/j.ajkd.2015.10.011_bib26","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1161\/01.CIR.0000149806.01354.BF","article-title":"Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study","volume":"110","author":"Tokmakova","year":"2004","journal-title":"Circulation"},{"issue":"18","key":"10.1053\/j.ajkd.2015.10.011_bib27","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"7438","key":"10.1053\/j.ajkd.2015.10.011_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)","volume":"328","author":"Marre","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0168-8227(01)00289-3","article-title":"Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM)","volume":"55","author":"Katayama","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib30","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2337\/diacare.23.12.1823","article-title":"Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial","volume":"23","author":"O'Hare","year":"2000","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1053\/j.ajkd.2015.10.011_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/diacare.21.1.104","article-title":"Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM","volume":"21","author":"Crepaldi","year":"1998","journal-title":"Diabetes Care"},{"issue":"9069","key":"10.1053\/j.ajkd.2015.10.011_bib32","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.ajkd.2015.10.011_bib33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2337\/diacare.20.10.1576","article-title":"Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria","volume":"20","author":"Ahmad","year":"1997","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1053\/j.ajkd.2015.10.011_bib34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0272-6386(96)90158-4","article-title":"Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial","volume":"27","author":"Ihle","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/BF00403306","article-title":"The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria","volume":"39","year":"1996","journal-title":"Diabetologia"},{"issue":"9","key":"10.1053\/j.ajkd.2015.10.011_bib37","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0895-7061(95)00162-I","article-title":"Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group","volume":"8","author":"Trevisan","year":"1995","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0002-9343(99)80226-5","article-title":"The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group","volume":"99","author":"Laffel","year":"1995","journal-title":"Am J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"issue":"20","key":"10.1053\/j.ajkd.2015.10.011_bib40","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0272-6386(12)70256-1","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy","volume":"20","author":"Bauer","year":"1992","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(98)00056-4","article-title":"A\u00a0randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia","volume":"104","author":"Foucan","year":"1998","journal-title":"Am J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib43","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/BF00577736","article-title":"Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study","volume":"72","author":"Capek","year":"1994","journal-title":"Clin Invest"},{"issue":"8","key":"10.1053\/j.ajkd.2015.10.011_bib44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","article-title":"Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients","volume":"118","author":"Ravid","year":"1993","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2337\/diacare.24.5.919","article-title":"Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes","volume":"24","author":"Bojestig","year":"2001","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib46","first-page":"327","article-title":"Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy","volume":"7","author":"O'Donnell","year":"1993","journal-title":"J\u00a0Hum Hypertens"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1291\/hypres.29.253","article-title":"Effects of imidapril on left ventricular mass in chronic hemodialysis patients","volume":"29","author":"Matsumoto","year":"2006","journal-title":"Hypertens Res"},{"issue":"12 suppl 1","key":"10.1053\/j.ajkd.2015.10.011_bib48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0026-0495(98)90364-X","article-title":"Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study","volume":"47","author":"Nankervis","year":"1998","journal-title":"Metabolism"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib49","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.ajkd.2005.11.024","article-title":"Effect of ramipril on left ventricular mass in normotensive hemodialysis patients","volume":"47","author":"Yu","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2015.10.011_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD treatment trial","volume":"167","author":"Bowling","year":"2013","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib51","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"issue":"10","key":"10.1053\/j.ajkd.2015.10.011_bib52","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/CIRCULATIONAHA.110.964171","article-title":"Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies","volume":"123","author":"Tobe","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib53","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib54","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib55","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1291\/hypres.31.657","volume":"31","author":"Makino","year":"2008","journal-title":"Hypertens Res"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib56","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1053\/j.ajkd.2014.05.011","article-title":"Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial","volume":"64","author":"Kjaergaard","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2015.10.011_bib57","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3109\/0886022X.2010.502276","article-title":"Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"32","author":"Yilmaz","year":"2010","journal-title":"Ren Fail"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib58","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ndt\/gfm731","article-title":"Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease","volume":"23","author":"Zeltner","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib59","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clinthera.2008.03.006","article-title":"The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study","volume":"30","author":"Esnault","year":"2008","journal-title":"Clin Ther"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib60","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial","volume":"48","author":"Norris","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2015.10.011_bib61","first-page":"592","article-title":"[Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol\/L?]","volume":"44","author":"Zhang","year":"2005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib62","doi-asserted-by":"crossref","first-page":"c139","DOI":"10.1159\/000086714","article-title":"A\u00a0prospective open-label randomised trial of quinapril and\/or amlodipine in progressive non-diabetic renal failure","volume":"101","author":"MacGregor","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib63","first-page":"259","article-title":"Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina)","volume":"17","author":"Dalla Vestra","year":"2004","journal-title":"Diabetes Nutr Metab"},{"issue":"8","key":"10.1053\/j.ajkd.2015.10.011_bib64","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/01.hjh.0000133733.32125.09","article-title":"Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study","volume":"22","author":"Marre","year":"2004","journal-title":"J\u00a0Hypertens"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-139-2-200307150-00010","article-title":"Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study","volume":"139","author":"Li","year":"2003","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1053\/j.ajkd.2015.10.011_bib66","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","article-title":"No effect of enalapril on progression in autosomal dominant polycystic kidney disease","volume":"18","author":"van Dijk","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib67","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2015.10.011_bib68","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00004872-200110000-00023","article-title":"A\u00a0random comparison of fosinopril and nifedipine GITS in patients with primary renal disease","volume":"19","author":"Marin","year":"2001","journal-title":"J\u00a0Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2015.10.011_bib69","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ndt\/16.11.2158","article-title":"The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study","volume":"16","author":"Herlitz","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib70","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/ndt\/16.5.961","article-title":"Effect of lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies","volume":"16","author":"Cinotti","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib71","first-page":"375","article-title":"A\u00a0randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension","volume":"55","author":"Petersen","year":"2001","journal-title":"Clin Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib72","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.2337\/diacare.23.12.1725","article-title":"Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy","volume":"23","author":"Tarnow","year":"2000","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ajkd.2015.10.011_bib73","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0895-7061(00)00287-9","article-title":"Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study","volume":"13","author":"Kumagai","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2015.10.011_bib74","first-page":"S58","article-title":"Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?","volume":"63","author":"van Essen","year":"1997","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"10.1053\/j.ajkd.2015.10.011_bib75","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/diab.46.7.1182","article-title":"Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy","volume":"46","author":"Nielsen","year":"1997","journal-title":"Diabetes"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib76","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","article-title":"Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy","volume":"50","author":"Bakris","year":"1996","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/(SICI)1096-9136(199602)13:2<120::AID-DIA6>3.0.CO;2-F","article-title":"Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study","volume":"13","author":"Sano","year":"1996","journal-title":"Diabet Med"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib78","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/BF00403380","article-title":"Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study","volume":"37","author":"Elving","year":"1994","journal-title":"Diabetologia"},{"issue":"6958","key":"10.1053\/j.ajkd.2015.10.011_bib79","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","article-title":"Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure","volume":"309","author":"Hannedouche","year":"1994","journal-title":"BMJ"},{"issue":"6823","key":"10.1053\/j.ajkd.2015.10.011_bib80","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","article-title":"Renal protective effect of enalapril in diabetic nephropathy","volume":"304","author":"Bjorck","year":"1992","journal-title":"BMJ"},{"issue":"7","key":"10.1053\/j.ajkd.2015.10.011_bib81","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","article-title":"Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial","volume":"5","author":"Kamper","year":"1992","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib82","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ki.1992.309","article-title":"Long-term comparison between captopril and nifedipine in the progression of renal insufficiency","volume":"42","author":"Zucchelli","year":"1992","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib83","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00004872-200204000-00032","article-title":"PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial","volume":"20","year":"2002","journal-title":"J\u00a0Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2015.10.011_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.jhh.1000732","article-title":"Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function","volume":"13","author":"Fogari","year":"1999","journal-title":"J\u00a0Hum Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib85","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00044011-199816030-00007","article-title":"Antihypertensive effect and tolerability of perindopril in Indian hypertensive and type 2 diabetic patients: 1-year randomised, double-blind, parallel study vs atenolol","volume":"16","author":"Seedat","year":"1998","journal-title":"Clin Drug Investig"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib86","first-page":"399","article-title":"[The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors]","volume":"41","author":"Shi","year":"2002","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib87","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s001250050623","article-title":"Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria","volume":"39","author":"Schnack","year":"1996","journal-title":"Diabetologia"},{"issue":"6770","key":"10.1053\/j.ajkd.2015.10.011_bib88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bmj.302.6770.210","article-title":"Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria","volume":"302","year":"1991","journal-title":"BMJ"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib89","first-page":"185","article-title":"Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine","volume":"10","author":"Agardh","year":"1996","journal-title":"J\u00a0Hum Hypertens"},{"issue":"7","key":"10.1053\/j.ajkd.2015.10.011_bib90","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00228-005-0961-2","article-title":"Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria","volume":"61","author":"Fogari","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib91","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib92","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0011-393X(00)80014-4","article-title":"Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus","volume":"61","author":"Fogari Roberto","year":"2000","journal-title":"Curr Ther Res"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib93","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/08037051003802475","article-title":"Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function","volume":"19","author":"Shiga","year":"2010","journal-title":"Blood Press"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib95","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/hr.2009.44","article-title":"Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study","volume":"32","author":"Saruta","year":"2009","journal-title":"Hypertens Res"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib96","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib97","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2337\/dc06-2493","article-title":"Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART)","volume":"30","author":"Uzu","year":"2007","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ajkd.2015.10.011_bib98","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis\u2013a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2015.10.011_bib99","doi-asserted-by":"crossref","first-page":"c18","DOI":"10.1159\/000081790","article-title":"Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease","volume":"99","author":"Nutahara","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1291\/hypres.28.415","article-title":"An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency","volume":"28","author":"Nakamura","year":"2005","journal-title":"Hypertens Res"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2796.2003.01071.x","article-title":"Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment","volume":"253","author":"Usta","year":"2003","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib102","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2015.10.011_bib103","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1681\/ASN.2004110973","article-title":"Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease","volume":"16","author":"Krimholtz","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib104","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2015.10.011_bib105","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/hr.2013.63","article-title":"Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial","volume":"36","author":"Rakugi","year":"2013","journal-title":"Hypertens Res"},{"issue":"3","key":"10.1053\/j.ajkd.2015.10.011_bib106","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/hr.2012.183","article-title":"Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT)","volume":"36","author":"Yasuda","year":"2013","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1053\/j.ajkd.2015.10.011_bib107","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.jhh.1002264","article-title":"Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases","volume":"22","author":"Mimura","year":"2008","journal-title":"J\u00a0Hum Hypertens"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib108","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.amjmed.2012.06.028","article-title":"Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor","volume":"126","author":"Li","year":"2013","journal-title":"Am J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib109","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"19","key":"10.1053\/j.ajkd.2015.10.011_bib110","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib111","first-page":"315","article-title":"Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study","volume":"64","author":"Reyes-Marin","year":"2012","journal-title":"Rev Invest Clin"},{"issue":"6","key":"10.1053\/j.ajkd.2015.10.011_bib112","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CNP71617","article-title":"Beneficial effects of high-dose losartan in IgA nephritis","volume":"71","author":"Woo","year":"2009","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2169\/internalmedicine.45.1515","article-title":"A\u00a0five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy","volume":"45","author":"Shoda","year":"2006","journal-title":"Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib114","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3317\/jraas.2006.016","article-title":"Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients","volume":"7","author":"Deyneli","year":"2006","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib115","first-page":"509","article-title":"[Effect of irbesartan in proteinuric non-diabetic renal disease]","volume":"25","author":"de Gracia","year":"2005","journal-title":"Nefrologia"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib116","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.2000.00224.x","article-title":"Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy","volume":"58","author":"Lacourciere","year":"2000","journal-title":"Kidney Int"},{"issue":"23","key":"10.1053\/j.ajkd.2015.10.011_bib117","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib118","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2015.10.011_bib119","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib120","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2215\/CJN.01110905","article-title":"Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors","volume":"1","author":"Kanno","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1053\/j.ajkd.2015.10.011_bib121","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2015.10.011_bib122","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2015.10.011_bib123","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2015.10.011_bib124","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib125","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1291\/hypres.30.325","article-title":"Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy","volume":"30","author":"Ogawa","year":"2007","journal-title":"Hypertens Res"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib127","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0011-393X(99)90003-6","article-title":"The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial","volume":"60","author":"Muirhead","year":"2000","journal-title":"Curr Ther Res"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial","volume":"61","author":"Fernandez Juarez","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2015.10.011_bib129","first-page":"963","article-title":"[Combination therapy with losartan and fosinopril for early diabetic nephropathy]","volume":"23","author":"Huang","year":"2003","journal-title":"Di Yi Jun Yi Da Xue Xue Bao"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib130","first-page":"1061","article-title":"Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria","volume":"35","author":"Bilic","year":"2011","journal-title":"Coll Antropol"},{"issue":"4","key":"10.1053\/j.ajkd.2015.10.011_bib131","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1526-0968.2004.00142.x","article-title":"Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy","volume":"8","author":"Suzuki","year":"2004","journal-title":"Ther Apher Dial"},{"issue":"12","key":"10.1053\/j.ajkd.2015.10.011_bib132","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1291\/hypres.27.963","article-title":"Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy","volume":"27","author":"Horita","year":"2004","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1053\/j.ajkd.2015.10.011_bib133","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/eb-2012-100851","article-title":"The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment?","volume":"18","author":"Fuchs","year":"2013","journal-title":"Evid Based Med"},{"issue":"5","key":"10.1053\/j.ajkd.2015.10.011_bib134","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J\u00a0Hypertens"},{"issue":"16","key":"10.1053\/j.ajkd.2015.10.011_bib135","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1053\/j.ajkd.2015.10.011_bib136","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2015.10.011_bib137","doi-asserted-by":"crossref","first-page":"f5680","DOI":"10.1136\/bmj.f5680","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ"},{"issue":"9668","key":"10.1053\/j.ajkd.2015.10.011_bib138","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of\u00a0randomised controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615013128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615013128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:44:20Z","timestamp":1759459460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638615013128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":138,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0272638615013128"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.10.011","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}